Elliott R B, Chase H P
Department of Paediatrics, School of Medicine, Auckland, New Zealand.
Diabetologia. 1991 May;34(5):362-5. doi: 10.1007/BF00405010.
A controlled trial of oral nicotinamide to prevent the onset of diabetes mellitus in high risk children was conducted in two centres. The selection criteria were age less than 16 years, islet cell antibody greater than or equal to 80 IUs, and first phase insulin release less than 5th percentile. All of eight untreated control subjects have developed diabetes, whereas only 1 of 14 treated children has diabetes to date. This data suggests that nicotinamide has an effect in preventing Type 1 (insulin-dependent) diabetes and that randomized controlled studies are now indicated.
在两个中心进行了一项口服烟酰胺预防高危儿童糖尿病发病的对照试验。入选标准为年龄小于16岁、胰岛细胞抗体大于或等于80国际单位,以及第一阶段胰岛素释放低于第5百分位数。所有8名未接受治疗的对照受试者均已患上糖尿病,而迄今为止,14名接受治疗的儿童中只有1名患有糖尿病。这些数据表明烟酰胺对预防1型(胰岛素依赖型)糖尿病有作用,现在需要进行随机对照研究。